Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Heart Test Laboratories Inc. Warrant (HSCSW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/03/2025: HSCSW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -32.73% | Avg. Invested days 13 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/03/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 2817 | Beta 2.73 | 52 Weeks Range 0.02 - 0.09 | Updated Date 03/20/2025 |
52 Weeks Range 0.02 - 0.09 | Updated Date 03/20/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.09 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -62.95% | Return on Equity (TTM) -163.47% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 995735 |
Shares Outstanding - | Shares Floating 995735 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Heart Test Laboratories Inc. Warrant
Company Overview
History and Background
Heart Test Laboratories Inc. is a medical technology company focused on developing and commercializing novel cardiovascular diagnostic technologies through its MyoVistau00ae platform. The warrants give the holder the right to purchase shares of the common stock of Heart Test Laboratories at a predetermined price. The Company went public in July 2023.
Core Business Areas
- Diagnostic Technology: Develops and commercializes cardiovascular diagnostic technologies.
Leadership and Structure
Details about the leadership team are available on the Heart Test Laboratories Inc. website or in their SEC filings. Structure is typical of a small, publicly traded medical device company.
Top Products and Market Share
Key Offerings
- MyoVistau00ae platform: Non-invasive diagnostic technology for cardiac assessment. Market share information is not readily available as the product is relatively new to the market. Competitors include traditional ECG manufacturers such as GE Healthcare, Philips Healthcare, and Medtronic. Revenue is not readily available since the company is in early growth stages.
Market Dynamics
Industry Overview
The cardiovascular diagnostics market is growing due to aging populations, increasing prevalence of heart disease, and advancements in diagnostic technologies.
Positioning
Heart Test Laboratories aims to disrupt the traditional ECG market with its MyoVistau00ae platform by providing more comprehensive cardiac assessments.
Total Addressable Market (TAM)
The global cardiac monitoring and diagnostic devices market is projected to reach billions of dollars. Heart Test Laboratories is positioned to capture a portion of this market with its innovative MyoVistau00ae technology.
Upturn SWOT Analysis
Strengths
- Innovative MyoVistau00ae platform
- Potential for improved cardiac assessment
- Focus on non-invasive diagnostics
Weaknesses
- Limited commercialization experience
- Dependence on single product (MyoVista)
- Limited financial resources compared to larger competitors
Opportunities
- Expansion into new markets
- Partnerships with healthcare providers
- Increased adoption of non-invasive diagnostics
Threats
- Competition from established players
- Regulatory hurdles
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- GE
- PHG
- MDT
Competitive Landscape
Heart Test Laboratories has the advantage of novel technology but faces significant competition from established medical device companies with greater resources and market presence.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is in early stages. Monitor revenue and user growth.
Future Projections: Future growth depends on the successful commercialization of the MyoVistau00ae platform. Analyst estimates are essential for future projections.
Recent Initiatives: Recent initiatives include commercialization efforts and partnerships.
Summary
Heart Test Laboratories, through its MyoVista platform, shows promise in cardiac diagnostics, but the company is small with low financials and relatively new in the market. Its success hinges on successfully commercializing and rapidly growing revenue. Heart Test Laboratories faces significant competition from larger, more established players. Regulatory and reimbursement hurdles also present challenges.
Similar Companies
GE
GE Aerospace
GE
GE Aerospace
MDT
Medtronic PLC
MDT
Medtronic PLC
PHG
Koninklijke Philips NV ADR
PHG
Koninklijke Philips NV ADR
Sources and Disclaimers
Data Sources:
- SEC Filings
- Heart Test Laboratories Inc. Website
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Market share estimates are approximate and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Heart Test Laboratories Inc. Warrant
Exchange NASDAQ | Headquaters Southlake, TX, United States | ||
IPO Launch date 2022-06-15 | CEO, President & Chairman of the Board of Directors Mr. Andrew Simpson | ||
Sector Healthcare | Industry Medical Devices | Full time employees 15 | Website https://heartsciences.com |
Full time employees 15 | Website https://heartsciences.com | ||
HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to enhance its clinical utility. It is developing artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction and conventional ECG information in the same test; and MyoVista Insights, a cloud-based platform to host AI-ECG algorithms on an ECG hardware agnostic basis. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.